Claims
- 1. A compound having the structure: wherein(a) R1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R2, CH2OH, S(O)2R2, C(O)NHR2, C(O)NHS(O)2R2, or tetrazole; wherein R2 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring; (b) X is selected from the group consisting of CH═C═CH, CH═CH, CH═N, C(O) and C(O)Y; wherein Y is selected from the group consisting of O, S and NH; (c) Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring Z is attached via a Carbon member atom; and (d) any optical isomer, diastereomer, entinaomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable amide, ester, or imide thereof.
- 2. The compound of claim 1 wherein R1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R2, C(O)NHS(O)2R2, or tetrazole.
- 3. The compound of claim 2, wherein X is CH—C═CH or C(O)Y.
- 4. The compound of claim 3, wherein Z is monocyclic.
- 5. The compound of claim 4, wherein Z is selected from the group consisting of: phenly, thienyl, and furanyl.
- 6. The compound of claim 5, wherein Z substituted with one substitute, said one substitutent being selected from the group consisting of: lower alkyl, halo, and haloalkyl.
- 7. The compound of claim 6, wherein R1 is CO2H or CO2R2.
- 8. The compound of claim 7, wherein R2 is selected from the group consisting of methyl, ethyl and isopropyl.
- 9. The compound of claim 2, wherein X is CH═CH, CH—N, or C(O).
- 10. The compound of claim 9, wherein Z is bicyclic.
- 11. The compound of claim 10, wherein Z is a bicyclic heteroaromatic ring.
- 12. The compound of claim 11, wherein Z is selected from the group consisting of henzo[β]thiazolyl, benzo[β]thiophenyl and henzoxazoyl.
- 13. The compound of claim 12, wherein Z is substituted with one subtituent, wherein the substituent is selected from the group consisting of lower alkyl, halo and haloalkyl.
- 14. The compound of claim 13, wherein R1 is C(O)2H or CO2R2.
- 15. The compound of claim 14, wherein R2 is selected from the group consisting methyl, ethyl and isopropyl.
- 16. A method of treating or preventing a bone disorder in human or other animal subject in need of such treatment by administering to said human other animal subject a compound having the structure: wherein(a) R1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R2, CH2OH, S(O)R2, C(O)NHR2, C(O)NHS(O)2R2, or tetrazole; wherein R2 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring; (b) X is selected from the group consisting of CH═C═CH, CH═CH, CH═N, C(O) and C(O)Y, wherein Y is selected from the group consisting of O, S and NH; (c) Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring Z is attached via a Carbon member atom; and (d) any optical isomer, diastereomer, enantiomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable amide, ester, or imide thereof.
- 17. The method of claim 16, wherein the bone disorder is selected from the group consisting of osteoporosis, osteopenia and bone fracture.
- 18. The method of claim 17, wherein the compound is administered transdermally.
- 19. A method of treating glaucoma, said method comprising administering to a human or other animal a safe and effective amount of a compound according to the structure: wherein(a) R1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R2, CH2OH, S(O)2R2, C(O)NHR2, C(O)NHS(O)2R2, or tetrazole; wherein R2 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring; (b) X is selected from the group consisting of CH═C═CH, CH═CH, CH═N, C(O) and C(O)Y; wherein Y is selected from the group consisting of O, S and NH; (c) Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring Z is attached via a Carbon member atom; and (d) any optical isomer, diastereomer, enantiomer of the above structure or a pharmaceutically acceptable salt, or bio-hydrolyzable amide, ester, or imide thereof.
- 20. The method of claim 19, wherein the compound is administered topically.
Parent Case Info
This application is a 371 of PCT/US00/05299, filed Feb. 29, 2000, which claims benefit of Provisional application Ser. No. 60/122,929, filed Mar. 5, 1999.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US00/05299 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/51979 |
9/8/2000 |
WO |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
2000051979 |
Sep 2000 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/122929 |
Mar 1999 |
US |